Sign inThe company said additional patients in expanded cohorts showed sustained vision, anatomy, and pharmacokinetic benefits, with Phase 1b/2 data still expected in the first half of 2027.
SEC filing
CALM-1 hit its primary endpoint but CALM-2 did not, and GSK said the combined data will not change patient care.
SEC filing (2)
The clinical-stage pain biotech disclosed positive Phase 3-track abdominoplasty data for lead candidate LTG-001 and plans Phase 3 bunionectomy and safety trials in the second half of 2026.
SEC filing
The July 16, 2026 amendment cancels one note and issues two replacement notes without changing the total principal amount outstanding.
SEC filing
The San Diego preclinical testing company will sell shares and warrants at $0.85 apiece to one healthcare-focused institutional investor, with closing expected July 17, 2026.
SEC filing
The board approved lump sum retention payments for four named executives on July 13, 2026, replacing previously guaranteed 2026 bonus amounts.
SEC filing
The Nasdaq-listed biopharma registered a new prospectus supplement covering additional stock sales through JonesTrading after selling $11 million under a prior agreement.
SEC filing
The company can now sell shares periodically through D. Boral Capital under a new sales agreement filed July 17, 2026.
SEC filing
The filing shows shares outstanding fell to about 3.5 million after a May reverse split, with continued going concern and default disclosures.
SEC filing
Xeris Biopharma Holdings finished privately negotiated exchanges and a separate conversion of its 8.00% Convertible Senior Notes due 2028, leaving none outstanding as of July 15, 2026.
SEC filing
The San Antonio biopharmaceutical company registered a Nasdaq offering priced around $0.51 per share, with proceeds slated for its Entolimod program and general corporate use.
SEC filing
Richard Lowenthal left the board and Sarina Tanimoto exited as chief medical officer on July 15, 2026, with both receiving additional cash payments tied to severance terms.
SEC filing
The board approved a new equity plan on July 13, 2026, replacing five prior plans and reserving nearly 12 million shares for future awards.
SEC filing
The Nevada biotech is registering shares and pre-funded warrants through placement agent ThinkEquity while awaiting Phase 2b Parkinson's data expected late summer 2026.
SEC filing
The clinical-stage antiviral company registered a prospectus supplement dated July 17, 2026 to sell up to $4,018,069 in common stock through an at-market sales agreement.
SEC filing
The agreement, dated July 9, 2026, is not yet effective under its own terms pending a seven-day revocation window.
SEC filing (2)
The combined company gains Kira's complement and B-cell programs alongside Jasper's briquilimab, with cash expected to last into the second half of 2028.
SEC filing
The company amended a December 2025 filing to detail severance and benefits following Tooman's December 14, 2025 separation.
SEC filing
The company's fiscal 2026 Annual Report and CEO update cover cash position, a Southeast Asia commercial agreement, an options exercise, and restored Nasdaq bid-price compliance.
SEC filing
The clinical-stage oncology company disclosed plans to list on Nasdaq, with lead programs in EGFR-mutant lung cancer and AML/MDS, alongside a $60.6 million 2025 net loss.
SEC filing
The companies developed a lipid nanoparticle version of Aramchol designed to reach heart tissue instead of the liver, according to a July 16, 2026 filing.
SEC filing
The company expects about $9.1 million in net proceeds after fees, with shares priced at $1.05 and insiders paying $1.455 per share.
SEC filing
WAKIX net revenue reached roughly $261 million as Glenn Reicin departs and Stephen Mollichella becomes interim finance chief.
SEC filing
The company cited FDA feedback on data formatting as the reason for the delay, and reported cash of $174.9 million funding operations into third quarter of 2027.
SEC filing
The same 8-K disclosing new Pfizer/BioNTech suits and the $230M buyback also reveals a terminated RSV agreement and litigation bonuses for Arbutus executives.
SEC filing
The July 14, 2026 meeting produced shareholder approval for three directors, an equity plan increase, and a near 2.5-fold rise in authorized shares.
SEC filing
Arcutis Biotherapeutics expanded its board to ten members, naming Mirum Pharmaceuticals co-founder and CEO Christopher Peetz as a new independent Class III director effective July 15, 2026.
SEC filing
The Nasdaq-listed biopharma named CSO Yue Xiong, industry veteran Maxwell Kirkby, and biotech executive Claire Weston to its board.
SEC filing
Abbott lifted its full-year adjusted EPS range to $5.45-$5.60 as it advanced trials in coronary lithotripsy, cardiac ablation, and left atrial appendage closure.
SEC filing